GM Advisory Group LLC Purchases 1,575 Shares of Axon Enterprise, Inc $AXON

GM Advisory Group LLC boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 61.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,158 shares of the biotechnology company’s stock after acquiring an additional 1,575 shares during the quarter. GM Advisory Group LLC’s holdings in Axon Enterprise were worth $1,766,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of AXON. Evergreen Capital Management LLC grew its position in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Axon Enterprise by 0.5% in the third quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock valued at $2,848,000 after acquiring an additional 19 shares in the last quarter. CWA Asset Management Group LLC lifted its stake in Axon Enterprise by 5.2% in the fourth quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 19 shares during the period. Synergy Financial Group LTD lifted its stake in Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 19 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Axon Enterprise by 1.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $597.04 on Friday. The firm’s fifty day moving average is $437.68 and its two-hundred day moving average is $482.40. The firm has a market cap of $48.12 billion, a price-to-earnings ratio of 239.78, a PEG ratio of 12.18 and a beta of 1.38. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The company had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.Axon Enterprise’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.47 earnings per share. Research analysts expect that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AXON shares. Barclays cut their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. TD Cowen dropped their target price on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Piper Sandler reiterated an “overweight” rating and issued a $674.00 price target on shares of Axon Enterprise in a report on Monday, June 15th. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, UBS Group decreased their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Insiders Place Their Bets

In related news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at approximately $24,855,000. The trade was a 2.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the sale, the insider owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 48,989 shares of company stock valued at $24,090,083. 4.20% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.